STOCK TITAN

Pyxis Oncology Inc - PYXS STOCK NEWS

Welcome to our dedicated news page for Pyxis Oncology (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pyxis Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pyxis Oncology's position in the market.

Rhea-AI Summary
Pyxis Oncology, Inc. (Nasdaq: PYXS) extends cash runway to 2026, reports $134.4 million in cash, and announces Phase 1 trial progress for PYX-201 and PYX-106 programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
earnings
-
Rhea-AI Summary
Pyxis Oncology announces acceptance of four abstracts for poster presentation at SITC 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary
Pyxis Oncology to participate in two upcoming investment conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
conferences
Rhea-AI Summary
Pyxis Oncology completes acquisition of Apexigen, strengthening ADC platform and expanding pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
acquisition
-
Rhea-AI Summary
Pyxis Oncology, a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, reported financial results for Q2 2023. The company ended the quarter with $144.1 million in cash and short-term investments, supporting operations until 1H 2025. The acquisition of Apexigen, Inc. is expected to close in August. The Phase 1 trials for PYX-201 and PYX-106 are on track, with preliminary data expected in late 2023 and early 2024 respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
earnings
-
Rhea-AI Summary
Pyxis Oncology, Inc. (Nasdaq: PYXS) to Present Company Overview at BTIG Virtual Biotechnology Conference on August 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pyxis Oncology, Inc. has dosed the first subject in the Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate. The company has also initiated the second dose level in the Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate. Preliminary data from both trials are expected in late-2023/early-2024. Pyxis Oncology will present at the Jefferies Healthcare Conference on June 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
-
News
Rhea-AI Summary
Pyxis Oncology to acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. The acquisition positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation and expands their clinical pipeline into Phase 2. Sotigalimab, a CD40 agonist, has demonstrated rapid, deep, and durable responses across difficult-to-treat tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.46%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
earnings
Pyxis Oncology Inc

Nasdaq:PYXS

PYXS Rankings

PYXS Stock Data

247.65M
39.26M
21.97%
29.84%
3.65%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About PYXS

pyxis oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.